| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| rosiglitazone + metformin | aurora kinase a | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neoplasms[MeSHID:D009369] Complications of Diabetes Mellitus[MeSHID:D048909] |
NA | phase 3 | unknown |
| rosiglitazone + metformin | aurora kinase b | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neoplasms[MeSHID:D009369] Complications of Diabetes Mellitus[MeSHID:D048909] |
NA | phase 3 | unknown |
| rosiglitazone + metformin | fibroblast growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neoplasms[MeSHID:D009369] Complications of Diabetes Mellitus[MeSHID:D048909] |
NA | phase 3 | unknown |
| rosiglitazone + metformin | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neoplasms[MeSHID:D009369] Complications of Diabetes Mellitus[MeSHID:D048909] |
NA | phase 3 | unknown |
| rosiglitazone + metformin | peroxisome proliferator-activated receptor gamma | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Neoplasms[MeSHID:D009369] Complications of Diabetes Mellitus[MeSHID:D048909] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||